

Pfizer Announces an Independent Medical Education Grant RFP

Improving RCC Patient Outcomes

Competitive Grant Program - internal Pfizer review process

I. Background

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all **independent medical education grants**, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

II. Eligibility

Geographic Scope:	 Primary geography of interest: United States Secondary geography of interest: The five European countries of France, Germany, Italy, Spain and United Kingdom Projects may take place in or focus on learners in just one country or can have multi-country or cross-region reach. Applicants are encouraged to apply for support for programs within their primary area of geographic strength or expertise.
Applicant Eligibility Criteria	• The following types of organizations may apply: patient advocacy groups, nursing or pharmacy schools; healthcare institutions (both large and small); professional associations and societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
	 If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. all institutions must have a relevant role and the requesting organization must have a key role in the project.
	 For projects offering continuing education credit, the requesting organization must be accredited.

III. Requirements

Date RFP Issued	February 8, 2022
Clinical Area	Renal Cell Carcinoma (RCC)
General Area of Interest for this RFP:	The current standard of care in the treatment of first-line mRCC is combination immunotherapy with or without tyrosine kinase inhibitors.
	In this setting, therapy management and/or adverse-event management are important components of care that may improve outcomes for patients with RCC.
	Understanding adverse event etiology especially when overlapping toxicities are a concern may be an important consideration when treating first-line mRCC.





General Area of Interest for this RFP: (continued)	Projects that will be considered for Pfizer support will focus only on two areas:
	 Nursing or pharmacist education programs or resources that nurses or pharmacists can use as they care for patients with RCC
	Patient education programs or resources that patients can use as they make decisions about their own care and treatment
	Under this RFP, it is <u>not</u> our intent to support CME/medical education programs for physicians. It is also not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.
Target Audience:	1. Nurses, and/or pharmacists who care for patients with RCC
	2. RCC patients and their caregivers
Expected Approximate Monetary Range of Grant Applications:	 Individual projects requesting up to \$200,000 will be considered. The estimated total available budget related to this RFP is \$500,000.
	 Expected typical grant range: \$20,000 to \$200,000. For example, smaller, local, or single healthcare institution projects should be at the lower end of this range.
Key Dates:	RFP release date: February 8, 2022
	Grant Application due date: March 22, 2022
	Please note the deadline is 23:59 Eastern Standard Time (e.g. New York, GMT -5).
	Anticipated Grant Award Notification Date: April 19, 2022
	Grants will be distributed following a fully executed agreement.
	 Approximate anticipated Project Start and End Dates: June 2022 to December 2024 (projects may be shorter; maximum grant length is 2 years)





How to Submit:	 Please go to <u>www.cybergrants.com/pfizer/knowledge</u> and sign in. First-time users should click "Create your password". [Note: there are individual portals for each grant application type (e.g., knowledge, LOI, research full proposal, and QI full proposal). Please be sure to use the URL above.] Click the "Start A New Knowledge Gap Application" button. In the application: For the question "What type of request are you submitting?" select Response to a Request for Proposal (RFP)
	 For the question "Are you replying to a Request for Proposal (RFP) as part of the Competitive Grant Program?" select Yes
	 Select the following Competitive Grant Program Name: 2022 Onc G: Improving RCC Patient Outcomes
	 Select the following Primary Area of Interest: Oncology – Genitourinary - RCC
	Requirements for submission:
	Complete all required sections of the online application and upload your project proposal (see Appendix) in the General RFP Submission field.
	 If you encounter any technical difficulties with the website, please click the "Technical Questions" link at the bottom of the page.
	IMPORTANT: Be advised applications submitted after the due date will not be reviewed by the committee.
Questions:	If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Jacqueline Waldrop (<u>Jacqueline.Waldrop@Pfizer.com</u>) with the subject line "2022 Onc G: Improving RCC Patient Outcomes"
Grant Agreements:	 If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click <u>here</u> to view the core terms of the agreement. Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety.
Review and Approval Process	Grant requests received in response to this RFP will be reviewed by Pfizer colleagues to make final grant decisions.
Mechanism by which Applicants will be Notified:	 All applicants will be notified via email by the dates noted above. Applicants may be asked for additional clarification during the review period.





Appendix A General RFP Submission Requirements

Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Please include the following:

Goals and Objectives	 Briefly state the overall goal of the project. List the objectives you plan to meet with your project, in terms of learning and expected outcomes.
Needs Assessment for the Project	 Include a description of your organization's needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.
Target Audience	• Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.
Project Design and Methods	 Describe the planned project, the educational approach, and the way the planned methods address the established need.
Innovation	 Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.
Evaluation and Outcomes	 In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.
Dissemination Plan	 Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.





Improving RCC Patient Outcomes

Anticipated Project Timeline	 Provide an anticipated timeline for your project including project start/end dates.
Additional Information	 If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.
Organization Detail	• Describe the attributes of the institutions/organizations that will support and facilitate the execution of the project, the leadership of the proposed project, and the specific role of each institution in the proposed project.
Budget Narrative	 Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application While estimating your budget please keep the following items in mind: Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeutic assets (prescription or non-prescription). Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer.



